<DOC>
	<DOCNO>NCT00621868</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety pharmacokinetics ASP1941 male female patient type 2 diabetes mellitus</brief_summary>
	<brief_title>A Phase 2 Study ASP1941 Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Established diagnosis type 2 diabetes mellitus Fasting serum Cpeptide level &gt; 0.6 ng/mL HbA1c 7.0 10.0 % Body Mass Index 20 45 kg/m2 Serum creatinine &gt; upper limit normal Proteinuria ( albumin/creatinine ratio &gt; 300 mg/g ) Dysuria and/or urinary tract infection Significant renal , hepatic cardiovascular disease Ketosis Hypertension Severe gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>ASP1941</keyword>
</DOC>